Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy.

De Luca G, Navarese EP, Cassetti E, Verdoia M, Suryapranata H.

Am J Cardiol. 2011 Jan 15;107(2):198-203. doi: 10.1016/j.amjcard.2010.08.063. Review.

PMID:
21211597
2.

Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.

De Luca G, Marino P.

Am J Emerg Med. 2009 Jul;27(6):683-90. doi: 10.1016/j.ajem.2008.05.021.

PMID:
19751625
3.
4.

Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.

Tricoci P, Newby LK, Hasselblad V, Kong DF, Giugliano RP, White HD, Théroux P, Stone GW, Moliterno DJ, Van de Werf F, Armstrong PW, Prabhakaran D, Rasoul S, Bolognese L, Durand E, Braunwald E, Califf RM, Harrington RA.

Circ Cardiovasc Qual Outcomes. 2011 Jul;4(4):448-58. doi: 10.1161/CIRCOUTCOMES.110.960294. Epub 2011 Jun 28. Review.

5.

Antiplatelet intervention in acute coronary syndrome.

Arora RR, Rai F.

Am J Ther. 2009 Sep-Oct;16(5):e29-40. doi: 10.1097/MJT.0b013e31804c7238. Review.

PMID:
19092648
6.
7.
8.
9.

Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis.

De Luca G, Gibson CM, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U, Dudek D, Arntz HR, Zorman S, Gabriel HM, Emre A, Cutlip D, Biondi-Zoccai G, Rakowski T, Gyongyosi M, Marino P, Huber K, van't Hof AW.

Heart. 2008 Dec;94(12):1548-58. doi: 10.1136/hrt.2008.141648. Epub 2008 May 12. Review.

10.
11.

Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.

Lefebvre CW, Hoekstra JW, Bonaca M, Giugliano R.

J Emerg Med. 2009 Feb;36(2):162-70. doi: 10.1016/j.jemermed.2007.10.020. Epub 2008 Mar 19.

PMID:
18353601
12.

Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.

Jolly SS, Faxon DP, Fox KA, Afzal R, Boden WE, Widimsky P, Steg PG, Valentin V, Budaj A, Granger CB, Joyner CD, Chrolavicius S, Yusuf S, Mehta SR.

J Am Coll Cardiol. 2009 Jul 28;54(5):468-76. doi: 10.1016/j.jacc.2009.03.062.

13.

Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial.

Stone GW, Bertrand ME, Moses JW, Ohman EM, Lincoff AM, Ware JH, Pocock SJ, McLaurin BT, Cox DA, Jafar MZ, Chandna H, Hartmann F, Leisch F, Strasser RH, Desaga M, Stuckey TD, Zelman RB, Lieber IH, Cohen DJ, Mehran R, White HD; ACUITY Investigators.

JAMA. 2007 Feb 14;297(6):591-602.

PMID:
17299194
14.

Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes.

Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Heeschen C, Hamm CW, Moliterno DJ, Califf RM, White HD, Kleiman NS, Théroux P, Topol EJ.

Circulation. 2001 Dec 4;104(23):2767-71.

15.

Routine upstream versus selective downstream administration of glycoprotein IIb/IIIa inhibitors in patients with non-ST-elevation acute coronary syndromes: a meta-analysis of randomized trials.

Sciahbasi A, Biondi-Zoccai G, Romagnoli E, Valgimigli M, Rasoul S, van't Hof A, Lioy E, Stone GW.

Int J Cardiol. 2012 Mar 8;155(2):243-8. doi: 10.1016/j.ijcard.2010.10.010. Epub 2010 Oct 28. Review.

PMID:
21035214
16.

Outcomes with the use of glycoprotein IIb/IIIa inhibitors in non-ST-segment elevation acute coronary syndromes.

Dabbous OH, Anderson FA Jr, Gore JM, Eagle KA, Fox KA, Mehta RH, Goldberg RJ, Agnelli G, Steg PG; GRACE Investigators.

Heart. 2008 Feb;94(2):159-65. Epub 2007 Jun 17.

PMID:
17575335
18.

Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE).

Brieger D, Van de Werf F, Avezum A, Montalescot G, Kennelly BM, Granger CB, Goodman SG, Dabbous OH, Agnelli G; GRACE Investigators.

Am Heart J. 2007 Jun;153(6):960-9.

PMID:
17540196
19.

Early glycoprotein IIb-IIIa inhibitors in primary angioplasty-abciximab long-term results (EGYPT-ALT) cooperation: individual patient's data meta-analysis.

DE Luca G, Bellandi F, Huber K, Noc M, Petronio AS, Arntz HR, Maioli M, Gabriel HM, Zorman S, DE Carlo M, Rakowski T, Gyongyosi M, Dudek D.

J Thromb Haemost. 2011 Dec;9(12):2361-70. doi: 10.1111/j.1538-7836.2011.04513.x.

20.

Supplemental Content

Support Center